Overview and Scope
Hypophosphatasia treatment refers to the treatment of an inherited disorder that affects the development of bones and teeth. This disorder, also called Rathbun disease, interferes with the mineralization process, which deposits calcium and phosphorus in developing bones and teeth.
Sizing and Forecast
The hypophosphatasia treatment market size has grown steadily in recent years. It will grow from $2.68 billion in 2023 to $2.81 billion in 2024 at a compound annual growth rate (CAGR) of 5.0%. The growth in the historic period can be attributed to limited treatment options, increasing awareness, globalization of clinical trials, healthcare infrastructure development, investments and funding.
The hypophosphatasia treatment market size is expected to see strong growth in the next few years. It will grow to $3.45 billion in 2028 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to emerging therapies, increasing patient pool, precision medicine trends, government initiatives, increasing disease awareness. Major trends in the forecast period include advancements in therapeutic approaches, research and development initiatives, market expansion and global reach, collaborations and partnerships, regulatory landscape.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/hypophosphatasia-treatment-global-market-report
Segmentation & Regional Insights
The hypophosphatasia treatment market covered in this report is segmented –
1) By Type: Odontohypophosphatasia, Pseudohypophosphatasia, Other Types
2) By Treatment: Enzyme Replacement Therapy, Medication, Surgery, Other Treatments
3) By Route of Administration: Oral, Injectable
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
North America was the largest region in the hypophosphatasia treatment market in 2023. The regions covered in the hypophosphatasia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9424&type=smp
Major Driver Impacting Market Growth
The increasing investments in biomedical research activities are expected to propel the growth of the hypophosphatasia treatment market going forward. Investments in biomedical research activities refer to the investments made for the verification of biomedical science theories through scientific research techniques and the expansion of information regarding unique aspects of human health. Investments in biomedical research help in the development of new drugs and therapies for the quick and better treatment of hypophosphatasia, a rare inherited bone disorder. For instance, in September 2023, according to a report published by Centers for Medicare & Medicaid Services, a US-based federal agency, national health expenditure experienced a 2.7% growth in 2021, reaching $4.3 trillion, equivalent to $12,914 per person, and constituting 18.3% of the Gross Domestic Product (GDP). Over the period from 2022 to 2031, the average growth in national health expenditure is projected to be 5.4%, surpassing the average GDP growth of 4.6%. This trajectory is expected to result in an increase in the health spending share of GDP from 18.3% in 2021 to 19.6% in 2031. Therefore, the increasing investments in biomedical research activities are driving the growth of the hypophosphatasia treatment market.
Key Industry Players
Major players operating in hypophosphatasia market are focusing on research innovation and its publication for development and potential approved medicine for hypophosphatasia diseases. Research innovation refers to the creation and development of new ideas, processes, technologies, or methodologies that contribute to advancements in a particular field of study. For instance, in June 2021, Aruvant Sciences, a US-based clinical-stage biopharmaceutical company, announced the publication of data on ARU-2801, a potentially curative gene therapy for individuals with hypophosphatasia (HPP), and as an advocacy partnership. The publications and presentations are significant milestones in the development and potential approval of ARU-2801 for the treatment of HPP. Additionally, the advocacy partnership demonstrates Aruvant’s commitment to supporting and advancing the care of individuals with rare diseases, such as HPP.
The hypophosphatasia treatment market report table of contents includes:
1. Executive Summary
2. Hypophosphatasia Treatment Market Characteristics
3. Hypophosphatasia Treatment Market Trends And Strategies
4. Hypophosphatasia Treatment Market – Macro Economic Scenario
5. Global Hypophosphatasia Treatment Market Size and Growth
….
31. Global Hypophosphatasia Treatment Market Competitive Benchmarking
32. Global Hypophosphatasia Treatment Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Hypophosphatasia Treatment Market
34. Hypophosphatasia Treatment Market Future Outlook and Potential Analysis
35. Appendix
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
